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A B S T R A C T
Purpose
Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide
therapeutic opportunities.
Patients and Methods
We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically
sun-damaged (CSD) melanoma with KIT amplifications and/or mutations. Patients received
imatinib 400 mg once per day or 400 mg twice per day if there was no initial response. Dose
reductions were permitted for treatment-related toxicities. Additional oncogene mutation screen-
ing was performed by mass spectroscopy.
Results
Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT
mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6
months (range, 3.7 to 27.1 months). Best overall response rate (BORR) was 29% (21% excluding
nonconfirmed responses) with a two-stage 95% CI of 13% to 51%. BORR was significantly
greater than the hypothesized null of 5% and statistically significantly different by mutation status
(7 of 13 or 54% KIT mutated v 0% KIT amplified only). There were no statistical differences in rates
of progression or survival by mutation status or by melanoma site. The overall disease control rate
was 50% but varied significantly by KIT mutation status (77% mutated v 18% amplified). Four
patients harbored pretreatment NRAS mutations, and one patient acquired increased KIT
amplification after treatment.
Conclusion
Melanomas that arise on mucosal, acral, or CSD skin should be assessed for KIT mutations. Imatinib
can be effective when tumors harbor KIT mutations, but not if KIT is amplified only. NRAS mutations
and KIT copy number gain may be mechanisms of therapeutic resistance to imatinib.
J Clin Oncol 31:3182-3190. © 2013 by American Society of Clinical Oncology
INTRODUCTION
The clinical behavior of melanomas arising in
mucosal and acral sites, such as palms, soles, and
nail beds, is distinct from that of cutaneous mel-
anoma. These melanoma subtypes do not result
from the usual risk factors of sun exposure and
family history.1-3 Because of their unique distri-
bution and similar incidence across races, these
melanomas have been linked to different genetic
alterations and behavior.4 Unfortunately, on the
development of metastatic disease, patient prog-
nosis remains poor.
Mutations and amplifications in the KIT onco-
gene have been discovered in mucosal and acral
melanomas as well as those arising on chronically
sun-damaged (CSD) skin.5-8 KIT mutations are un-
common. Large series reported KIT mutations in
11.9% of acral melanomas in China7 and 2% of
nonmucosal melanomas in Australia,9 lower inci-
dences than originally described. Approximately 70%
of KIT mutations are in the juxtamembrane region,
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thus predicting responsiveness to the tyrosine kinase inhibitor, ima-
tinib mesylate.10
Imatinib inhibits proliferation and induces apoptosis in gastro-
intestinal stromal tumor (GIST) cells as well as melanoma cells with an
activating KIT mutation.11 The discovery of KIT mutations in human
melanoma tumors thus presents a clear rationale for testing the activ-
ity of imatinib in this patient population. We conducted a multicenter
trial of imatinib in patients with metastatic melanoma arising from




Eligibility included history of primary melanoma arising from mucosa,
acral sites, or CSD skin (defined by the presence of solar elastosis or increased
abnormal elastin in the mid-upper dermis12 and determined as standard of
care within the pathology department at the institution where the patient was
treated before trial enrollment); unresectable stage III or IV melanoma; East-
ern Cooperative Oncology Group (ECOG) performance status 0 to 2; normal
end-organ function; and KIT mutation or amplification as determined by
quantitative polymerase chain reaction (qPCR) or fluorescent in situ hybrid-
ization (FISH). Primary exclusions included prior treatment with a KIT inhib-
itor or brain metastasis.
KIT Molecular Status
KIT mutational status was determined by PCR, high-performance liquid
chromatography, and DNA sequencing, with amplicons arising from exons 9,
11, 13, and 17. Additional oncogene mutation screening was performed on
pretreatment tissue from all treated patients via a mass spectroscopy-based
system (Sequenom, San Diego, CA) by using a panel of 643 hotspot mutations
across 53 cancer genes notably including exons 14 and 15 of KIT.13 KIT gene
amplification was assessed by qPCR.14 The threshold for increased KIT copy
number was set relative to normal samples with the 95% confidence level
according to Chebychev’s inequality using the formula mean  (4.47 
standard deviation). The threshold for positive was 5.29 copies of KIT relative
to GAPDH. KIT gene amplification was also evaluated by FISH in 4-m
paraffin sections (Appendix Fig A1, online only). KIT gene copy number was
determined in relationship to a chromosome 2 pericentromeric probe, which
corresponds to a region rarely subject to gain or loss in melanoma. A sample
(or histologically distinctive region) was scored as amplified if the probe:
centromere ratio was more than 1.50 (highly amplified  5.0).
Study Objectives and Statistics
The primary objectives of the study were to assess response rate (RR) per
Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and time to
progression (TTP). Secondary objectives included assessing tolerability and
overall survival (OS) and exploring the association between mutation status
and response to therapy. The study used a Simon two-stage design to compare
a null RR of 5% with an alternative RR of 20% with 84% power and a one-sided
type I error of 11%. The total sample size was 25 patients. Ten patients were
enrolled in the first stage, with one response required to proceed to the second
stage. Three responses among 25 patients were required for imatinib to be consid-
eredpromising.Astoppingrulewasaddedsuchthat if zero of 10 patients whose
tumors were not mutated but were amplified had a response, then only
patients with tumors that harbored mutations would be enrolled. Further
description of statistical methods are found in the Appendix (online only).
Study Agent Dosing and Toxicity
Patients were treated with imatinib 400 mg orally once per day until
disease progression. In other solid tumors, the optimal dose of imatinib is
dependent on mutational status of the tumor, with certain mutations showing
an improved RR to increased doses.15 Therefore, patients receiving 400 mg
once per day were permitted to increase to 400 mg twice per day on disease
progression. Treatment was discontinued for patients who progressed on 400
mg twice per day. Toxicities and adverse events (AEs) were classified according
to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Dose interruptions and reductions are described in the Appendix.
Radiographic Evaluation
18F-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography/
computed tomography (PET/CT) studies were obtained before and 1 month
following treatment initiation. Metabolic tumor response was classified by
using European Organisation for Research and Treatment of Cancer
(EORTC) criteria based on thresholds for percent change in maximum stan-
dardized uptake value (SUVmax). CT scans of chest, abdomen, and pelvis and
magnetic resonance imaging scans of the head were obtained at baseline, after
6 weeks of therapy, and at 2-month intervals. Anatomic tumor response was
classified by using RECIST 1.0. Assessments used SUVmax and metabolic
volume with 70% threshold region of interest for each lesion, up to a maxi-
mum of 10 lesions.
RESULTS
Enrollment occurred at nine medical centers between July 6, 2006, and
March 1, 2011. Of 213 patients screened, 25 (11.7%) were treated.
Appendix Table A1 (online only) summarizes mutational and ampli-
fication status by melanoma type. One treated patient was initially
described to have a KIT mutation by PCR but later mass spectroscopy
genomic assessment determined that the patient did not harbor a KIT
mutation or amplification. Data for this patient are not included in the
analyses. The resulting analytic sample size is 24. Note that a two-stage
design based on 24 patients has approximately 83% power to detect an
RR of at least 20% against a null of 5% while maintaining a one-sided
type I error of 11%. Therefore, losing one patient from the analysis did
not compromise the power of the study.
Molecular classification of the study population included eight
patients (33%) with KIT mutations, 11 (46%) with amplified KIT, and
five (21%) with both. Patients with both were classified as having
mutation (total 13). Nine patients (73%) were found to have muta-
tions in exon 11: L576P (4), insertion PYD577-582 (1), V559A (1),
V560D (1), deletion WKVVE 557-560 (1), and W557R (1). Other
mutation sites included exon 17: D820Y (1) and exon 13: K642E (3).
For patients who had KIT amplification by qPCR, the median copy
number was 8. However, only one patient with KIT amplification by
qPCR was confirmed to have high-level KIT amplification by FISH
validations. Note that qPCR was used for study screening and FISH
was performed retrospectively. Once the study had reached the ac-
crual goal for KIT wild-type but amplified tumors, qPCR was no
longer performed during the screening process. Thus, not all patients
had both qPCR and FISH testing. One patient with amplified KIT was
found after initial progressive disease (PD) to have had poor drug
absorption (whole pills were observed in the patient’s ostomy output)
in the setting of taking a prohibited medication (proton pump inhib-
itor). Thus, a protocol deviation was obtained to treat an eleventh
patient with KIT amplification.
Patients were predominantly female (75%) with M1c disease
(63%). The median age was 65 years (range, 42 to 84 years), and the
median ECOG performance status was zero (Table 1). Seventeen
patients (71%) had mucosal melanoma, six (25%) had acral mela-
noma, and one had CSD melanoma. All patients had undergone
cancer-directed surgery, with seven (29%) receiving radiation treat-
ment, six (25%) chemotherapy, and seven (29%) both. For the 13
patients receiving prior chemotherapy, the median number of thera-
pies was one (range, one to two). There were no statistically significant
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relationships between mutation status and other characteristics, al-
though patients with KIT-amplified tumors were slightly older.
At time of reporting, all patients were off study, with 88% stop-
ping as a result of PD. Median follow-up of living patients was 10.6
months (range, 3.7 to 27.1 months), with 23 (96%) having progressed
and 19 (79%) having died (Table 2). In all cases, death was attributed
to disease progression. There were no statistical differences in rates of
progression or survival by mutational status.
Response results are described in Table 2. The best overall re-
sponse rate (BORR) was 29% (two-stage 95% CI, 13% to 51%). Note
that RECIST responses were confirmed after 4 weeks except in two
cases (BORR was 20.8% when these two patients were excluded). The







PNo. % No. % No. %
Institution .34
Dana-Farber Cancer Institute 7 29.2 5 45.5 2 15.4
Massachusetts General Hospital 2 8.3 — — 2 15.4
Moffitt Cancer Center 5 20.8 2 18.2 3 23.1
University of Chicago 3 12.5 1 9.1 2 15.4
The Angeles Clinic 2 8.3 2 18.2 — —
University of Colorado 4 16.7 1 9.1 3 23.1
MD Anderson Cancer Center 1 4.2 — — 1 7.7
Age, years .4
Median 65 69 64
Range 42-84 55-84 42-80
Sex .36
Female 18 75 7 63.6 11 84.6
Male 6 25 4 36.4 2 15.4
Race .44
Unknown 1 4.2 — — 1 7.7
White 19 79.2 8 72.7 11 84.6
African American 1 4.2 1 9.1 — —
Asian 1 4.2 1 9.1 — —
Multiracial 1 4.2 1 9.1 — —
Other 1 4.2 — — 1 7.7
Ethnicity .22
Hispanic or Latino 3 12.5 — — 3 23.1
Non-Hispanic 21 87.5 11 100 10 76.9
Disease stage .53
M1a 1 4.2 1 9.1 — —
M1b 8 33.3 4 36.4 4 30.8
M1c 15 62.5 6 54.5 9 69.2
Melanoma subtype .24
Mucosal 17 70.8 6 54.5 11 84.6
Acral 6 25 4 36.4 2 15.4
CSD 1 4.2 1 9.1 — —
ECOG performance status .99
0 17 70.8 8 72.7 9 69.2
1 7 29.2 3 27.3 4 30.8
Site for KIT molecular testing .99
Primary 12 50 5 45.5 7 53.8
Metastatic 12 50 6 54.5 6 46.2
Prior radiation .24
No 10 41.7 3 27.3 7 53.8
Yes 14 58.3 8 72.7 6 46.2
Prior chemotherapy .44
No 11 45.8 4 36.4 7 53.8
Yes 13 54.2 7 63.6 6 46.2
Prior therapies
Median 1 1 1 —
Range 1-2 1-2 1-2
NOTE. Percentages are calculated down the columns (within type of mutation). Acral melanoma: six (11.8%; 90% CI, 5% to 22%) of 51 KIT mutations; mucosal
melanoma: 15 (14.6%; 90% CI, 9% to 22%) of 103 KIT mutations; chronically sun-damaged (CSD) melanoma: two (3.9%; 90% CI, 1% to 12%) of 51 KIT mutations.
P values compare amplified versus mutated KIT.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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BORR was significantly greater than the hypothesized null value of 5%
(P  .001). There was a highly statistically significant relationship
between best overall response and mutational status (Fisher’s exact
P  .003). BORR was statistically significantly different by mutational
status (7 [54%] of 13 had mutated KIT v 0% with amplified KIT;
Fisher’s exact P  .006). Twelve patients achieved partial response
(PR) or stable disease (SD) resulting in a disease control rate (DCR) of
50% (two-stage 95% CI, 29% to 71%). The DCR was significantly
related to KIT mutational status (77% mutated v 18% amplified;
Fisher’s exact P  .01).
All responses observed were in patients with tumors harboring a
KIT mutation. In contrast, nine of 12 with PD as best response had
KIT-amplified-only tumors. Patients with SD were evenly divided
between mutated and amplified. Individual patient data for KIT mu-
tation, PCR, and FISH copy number, TTP, and response are presented
in Table 3. There were no statistically significant differences in re-
sponse, progression, or survival status by melanoma type, although
notably, only mucosal primary tumors showed responses (BORR:
41% mucosal v 0% acral or CSD; P  .06).
Median TTP was 3.7 months (95% CI, 2.6 to 5.6 months).
Kaplan-Meier estimates of TTP by mutation and amplification status
as well as OS are shown in Figure 1. There was no significant difference
in TTP or OS by KIT status (mutated or amplified) or disease site
(mucosal v other). Median OS was 12.5 months (95% CI, 8.8 to 18.0
months). Patients received an average of 4 months of treatment (me-
dian, 3 months; range, 1 to 11 months). Those with KIT mutations
had significantly longer time on treatment compared with those with
amplified KIT (Wilcoxon rank sum P  .01).
Dose modifications were allowed on study and included
seven dose modifications for PD (400 to 800 mg). For five of the
dose increases, the patients continued to experience PD, and in
two patients, SD was achieved for 2 months before progression.
There were four dose reductions because of toxicity (400 to 300
mg): patient 1 had a best response of PR 2 months after starting
treatment, dose reduction at month 3, and was taken off study
for disease progression at month 5; patient 2 had a dose modi-
fication at month 4, best response of PR at month 6, and was
taken off treatment for unacceptable toxicity at month 9. The
other two patients had best response of PD in the context of
amplified KIT with NRAS mutations.
All patients reported AEs with three patients experiencing grade 4
events and seven patients describing a total of 17 grade 3 events. Grade
3 to 4 AEs are described by KIT molecular status in Appendix Table A2
(online only). The most commonly reported AEs were nausea
(n  17), fatigue (n  16), anemia (n  12), hyperglycemia (n  11),
and vomiting (n  10).
Seventeen patients underwent baseline and follow-up PET/CT.
Representative PET/CT showing RECIST and metabolic response is
demonstrated in Figure 2. Of 17 patients, four (24%) demonstrated
metabolic PD, eight (47%) SD, and five (29%) PR. Response rates,
BORR, and DCR compared for metabolic response classification are
shown in Appendix Table A3 (online only). There was agreement of
classification in 11 (65%) of 17 patients. The metabolic response at 1
month suggested a greater impact from therapy than measurements
on conventional cross-sectional imaging. Metabolic response agreed
with BORR in 15 (88%) of 17 patients. There were no statistical





Amplified KIT Mutated KIT
No. % No. % No. %
Best overall response
7 29.2 — — 7 53.8PR .003
SD 5 20.8 2 18.2 3 23.1
PD 12 50.0 9 81.8 3 23.1
BORR (CR  PR) .006
No 17 70.8 11 100.0 6 46.2
Yes 7 29.2 — — 7 53.8
Disease control (CR  PR  SD) .01
No 12 50.0 9 81.8 3 23.1
Yes 12 50.0 2 18.2 10 76.9
Progression
1 4.2 — — 1 7.7No .99
Yes 23 95.8 11 100.0 12 92.3
Survival status
5 20.8 1 9.1 4 30.8Alive .33
Dead 19 79.2 10 90.9 9 69.2
Reason off study
1 4.2 — — 1 7.7Unacceptable toxicity .99
Progressive illness 21 87.5 10 90.9 11 84.6
Intercurrent illness 1 4.2 — — 1† 7.7
Withdrew consent 1 4.2 1 9.1 — —
NOTE. P values compare amplified versus mutated KIT.
Abbreviations: BORR, best overall response rate; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
Patient 2 off study because of grade 3 bleeding/hemorrhage.
†Patient 14 ended study participation because of preceding and ongoing issues regarding ostomy strictures.
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differences in the proportions of patients who were classified as re-
sponders (metabolic, 29% v trial, 29%; McNemar’s test P  .99). The
DCR according to metabolic response classification was 77% (13 of
17). This was significantly different from observed RECIST DCR
(47% [eight of 17]; McNemar’s test P  .03), suggesting higher early
metabolic response.
Additional oncogene mutation screening was performed on pre-
treatment samples using mass spectroscopy. A panel that detects hot-
spot mutations across 53 genes, including KIT, BRAF, NRAS,
MAP2K1, PIK3CA, GNA11, and GNAQ, was run on all study patients
and revealed four patients with NRAS mutation (two with KIT ampli-
fication and two with KIT mutations). All four patients had PD as best
response. Two other patients who initially experienced a response had
a biopsy performed at the time of progression. These samples har-
bored the same KIT mutations as pretreatment with no additional
mutations. One of these (patient 16) did show amplification of KIT
copy number after treatment, increasing from 14.2 copies pretreat-
ment to 21.8 copies post-treatment.
DISCUSSION
The fundamental discoveries of BRAF,16 NRAS,17,18 KIT,5,6 GNAQ,19
and GNA1119 activating mutations in melanoma have highlighted its
biologic diversity. These have importantly altered melanoma classifi-
cation based on anatomic site of origin and genomic anomalies. Such
classification has striking therapeutic implications.20
Three previously completed phase II studies of imatinib in unse-
lected patients with melanoma failed to demonstrate clinical
activity.21-23 Not until genomic alterations in KIT were identified did
selection of patients become possible and the clinical efficacy of target-
ing KIT was demonstrated.24,25 Imatinib targeting KIT melanoma has
been reported recently in two other phase II studies. The first study,
using 400 mg twice per day, revealed an RR of 16% and median TTP of
3 months.8 The RR was superior with certain KIT mutations or
mutant:wild-type allelic ratio greater than one. In the second study
(imatinib dosing was the same as in our study), the median
progression-free survival was 3.5 months and DCR was 53.5%.26 In
No. at risk
 24 15 6 4 1 1 1 1 1
No. at risk
Amplified 11 6 2 1 0 0 0 0 0

















































































 24 22 18 15 10 8 6 3 2 1 0
No. at risk
Amplified 11 10 8 7 4 3 2 1 0 0 0
Mutated 13 12 10 8 6 5 4 2 2 1 0
0 3 6 9 12 15 18 2421 3027
Median TTP (months), 3.7
95% CI, 2.6 to 5.6
Mutated Median TTP (months), 12.9
 95% CI, 5.5 to 24.3
Amplified Median OS (months), 11.9
 95% CI, 4.5 to 16.2
 Log-rank P = .24
Mutated Median TTP (months), 3.9
 95% CI, 2.6 to 6.6
Amplified Median OS (months), 3.4
 95% CI, 1.0 to 5.7
 Log-rank P = .41
Median OS (months), 12.5
95% CI, 8.8 to 18.0
Fig 1. Kaplan-Meier curves for clinical efficacy by KIT mutational status. Time to progression (TTP) analysis. (A) All patients showed a median TTP of 3.7 months
(95% CI, 2.6 to 5.6 months). (B) Subset TTP analysis showed medians of 3.9 months (95% CI, 2.6 to 6.6 months) in those with mutations and 3.4 months (95%
CI, 1.0 to 5.7 months) in those with amplifications. Overall survival (OS) analysis for (C) all patients showed a median of 12.5 months (95% CI, 8.8 to 18.0 months)
with (D) subsets showing medians of 12.9 months (95% CI, 5.5 to 24.3 months) for those with mutations and 11.9 months (95% CI, 4.5 to 16.2 months) for
those with amplifications.
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nine of 10 patients experiencing a response, a mutation was found in
KIT exon 11 or 13. In our study, the overall DCR was 50%, with clear
superiority for tumors harboring KIT mutations over amplification.
Responses were witnessed only in patients whose tumors had KIT
mutations, and the median TTP (3.7 months) was not significantly
different between KIT-mutated and KIT-amplified disease. This study
included more KIT-amplified patients than did prior reports; it pro-
vides definitive evidence that activity of imatinib in a KIT-amplified
(without mutation) population is substantially limited. Our study
highlights the challenges of screening for KIT amplification, given that
results by qPCR were often not confirmed by a complementary FISH
method, perhaps reflecting genetic heterogeneity in KIT copy number
gains. Our study also confirms the feasibility of imatinib administra-
tion in melanoma because the AE profiles of three studies do not vary
substantially from that described in GIST.27
The importance of KIT as a therapeutic target has been demon-
strated in GIST. Imatinib provides 75% to 90% stable or responsive
disease with an 18-month median TTP. The mutational or amplifica-
tion rate of KIT in melanoma is lower (8.6% to 23.4% melanoma v
75% to 90% GIST) as are the RR and durability. Most KIT mutations
in melanoma are observed in exon 11 (similar to GIST) with a prepon-
derance of L576P mutations. This emphasizes the biologic diversity of
tumors that may be driven by similar oncogene activation, since addi-
tional factors influencing clinical benefit of KIT inhibition between
melanoma and GIST must exist. In our study, only patients with
mucosal melanoma demonstrated RECIST responses. Although not
statistically significant, that suggests the possibility that KIT biology
might vary even within different melanoma subtypes. Further studies
will be required to examine KIT within these subtypes since KIT
inhibitor responsiveness may be dependent on ETV1 expression, sim-
ilar to GIST,28 although nonresponsive tumors may have different
biology entirely. Despite these efficacy differences, recognition of KIT
mutations in melanoma has provided novel treatment opportunities
for this disease.
Given the low frequency of KIT mutations in melanoma,
continued collaborative efforts are required to understand the
clinical implications of individual mutations as well as resistance
mechanisms. Although therapeutic resistance in GIST primarily
involves acquisition of additional KIT mutations,29 resistant mech-
anisms in melanoma are seemingly more complex. De novo resis-
tance in melanoma may be due to pre-existing mutations in other
BA
DC
Fig 2. Representative computed tomog-
raphy and positron emission tomography
(PET) study of a responding patient.
Cross-sectional axial slices from (A,B)
computed tomography images and (C,D)
[18F]fluorodeoxyglucose PET ([18F]FDG-
PET) images at baseline (left) and after 1
month of therapy (right) show resolution
of FDG uptake and decrease in the size of
a right inguinal lymph node (gold arrow)
and a left perirectal soft tissue nodule
(blue arrow).
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oncogenes. In our study, four patients had NRAS mutations before
treatment. None of these patients had a response or sustained SD to
imatinib. These results suggest that MAPK and PI3K pathways
both play a role in resistance to KIT targeting in melanoma. This
hypothesis is strengthened by cell line models describing both PI3K
and MAPK pathways as important downstream outputs of acti-
vated KIT in melanoma.30 A separate mass spectroscopy– based
screening of 59 KIT-mutant melanoma samples observed no mu-
tations in BRAF and one NRAS exon 2 mutation. It appears that
NRAS mutations are a likely cause for primary resistance to KIT
targeting in some melanomas. This raises interesting possibilities
for future research assessing combinations of KIT inhibitors with
inhibitors of MAPK pathway members such as MEK. Little data are
currently available regarding acquired resistance. In our study, two
patients who experienced an initial response but subsequently
progressed were found on mass spectroscopy of post-treatment
biopsy to retain the original KIT mutation without a secondary
mutation. One of these tumors did show an increase in KIT copy
number from 14.2 to 21.8 copies. Thus, increase in amplification of
KIT may be a similar phenomenon to that described in BRAF
inhibitor resistance.31 This suggests that intermittent high-dose
KIT inhibitor therapy or monitoring of drug plasma concentra-
tions, as described in GIST,32 may be of interest to abrogate resis-
tance in the future. Given the diversity in mechanisms of BRAF
inhibitor resistance and the lack of secondary KIT mutations, it
seems likely that mechanisms of resistance to KIT inhibitors in
melanoma will be variable. However, on the basis of our experi-
ence, the MAPK pathway would be an obvious starting place for
further investigation.
The clinical efficacy of imatinib provides a rationale for patients
with primary mucosal, acral, or CSD melanomas to have their tumors
tested for KIT mutations. Pharmacologic concerns should also be
taken into consideration because drugs of greater potency and speci-
ficity could offer an improved therapeutic window and provide im-
proved efficacy for wild-type amplified tumors in addition to those
with mutations. Patients should be encouraged to participate in clin-
ical trials testing KIT inhibitors.
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Appendix
Methods (Statistics)
Differences in baseline demographic and disease characteristics between mutation groups were assessed by using a Wilcoxon rank
sum test for continuous variables or Fisher’s exact test for categorical variables. Best overall response rate (BORR) and disease control rate
(defined as the total of complete response, partial response, and stable disease) are presented with two-stage 95% CIs. The comparison of
BORR with hypothesized null rate of 5% was conducted by using exact binomial methods. Differences in response rates or disease control
rate by mutation status were assessed by using Fisher’s exact test. Time to progression and overall survival were presented by using the
method of Kaplan and Meier, with point-wise 95% CIs estimated by using log[-log(survival)] methodology. Equality of survival curves by
mutation status was assessed by using the log-rank test. Comparisons between the number of adverse events and months on treatment
were performed by using Spearman correlations. Agreement of response and disease control classifications based on metabolic response
and Response Evaluation Criteria in Solid Tumors (RECIST) BORR were conducted by using McNemar’s test. The relationship between
percent change in standardized uptake value and computed tomography longest diameter was assessed by using the Spearman correlation
coefficient. All P values are two-sided, with statistical significance defined as P  .05. There were no corrections for multiple comparisons.
Dose Interruptions and Reductions
If grade 2 nonhematologic toxicity was observed, imatinib was held until toxicity resolved to grade  1. Imatinib was then restarted
with no dose reduction. If grade 2 toxicity recurred, imatinib was held until resolution to grade  1 and then reduced to 300 mg. Therapy
was discontinued if grade 2 nonhematologic toxicity recurred. For grade 3 to 4 nonhematologic toxicity, imatinib was withheld until
toxicity resolved, and the dose was then reduced to 300 mg on restarting imatinib. If grade 3 to 4 toxicity recurred, therapy was
discontinued. For grade 3 to 4 hematologic toxicity, imatinib was held until grade  2 was achieved. If grade 3 to 4 hematologic toxicity
recurred (or lasted  2 weeks), imatinib was withheld until resolution to grade  2, and imatinib was restarted at 300 mg. If grade 3 to 4
toxicity recurred following dose reduction, therapy was discontinued.
Adverse Events by KIT Molecular Status
Patients with mutated KIT had a greater number of adverse event (AE) types than patients with amplified KIT (Wilcoxon rank sum
P  .02). In subgroup analysis of seven patients with grade 3 to 4 AEs, there was a relationship between number of grade 3 or 4 AEs per
patient and the number of months on treatment (Spearman correlation coefficient  0.77; P  .04). Patients with KIT mutation were
more likely to experience dermatologic (69% mutated [nine of 13] v 9% amplified [one of 11]; Fisher’s exact P  .005) or gastrointestinal
AEs (100% mutated [13 of 13] v 64% amplified [seven of 11]; Fisher’s exact P  .03). No other differences in AE incidence by mutation
status were noted.









No. % No. % No. % No. % No. % No. %
Screening Summary With Row Percents
Acral 5 9.8 — — 6 11.8 37 72.5 3 5.9 51
Mucosal 10 9.7 5 4.9 15 14.6 68 66.0 5 4.9 103
Chronically sun damaged 6 11.8 — — 2 3.9 36 70.6 7 13.7 51
Not provided 1 12.5 — — — — 4 50.0 3 37.5 8
All 22 10.3 5 2.3 23 10.8 145 68.1 18 8.5 213
Screening Summary With Column Percents
Acral 5 22.7 — — 6 26.1 37 25.5 3 16.7 51 23.9
Mucosal 10 45.5 5 100 15 65.2 68 46.9 5 27.8 103 48.4
Chronically sun damaged 6 27.3 — — 2 8.7 36 24.8 7 38.9 51 23.9
Not provided 1 4.5 — — — — 4 2.8 3 16.7 8 3.8
All 22 — 5 — 23 — 145 — 18 — 213 —
NOTE. Row percents are calculated within Type of Melanoma. Column percents are calculated within Mutational Status.
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Table A2. Worst Grade of AEs Presented by CTCAE Grade 3 and 4
Description of AE Patient No. Relationship to Treatment KIT Mutation Status
Life-threatening (grade 4)
Neutrophils/granulocytes 1 Probable Mutated
Hemoglobin 17 Probable Mutated
Dyspnea 19 Unlikely Mutated
Severe (grade 3)
Pruritus/itching 1 Definite Mutated
Hemoglobin 2 Possible Mutated
Leukocytes (total WBC) 2 Possible Mutated
Lymphopenia 2 Possible Mutated
GI hemorrhage (upper GI, not otherwise specified) 2 Unlikely Mutated
Low serum potassium (hypokalemia) 2 Possible Mutated
Lymphopenia 6 Probable Amplified
Low serum sodium (hyponatremia) 6 Unlikely Amplified
Fatigue (asthenia, lethargy, malaise) 8 Unknown Amplified
GI obstruction (duodenum) 12 Not related Mutated
GI stoma stricture/stenosis (including anastomotic) 12 Not related Mutated
Low serum potassium (hypokalemia) 12 Not related Mutated
Stomach pain 12 Not related Mutated
Extremity pain (limb) 17 Not related Mutated
GU obstruction (ureter) 17 Unlikely Mutated
Hemoglobin 19 Unlikely Mutated
Creatinine 19 Not related Mutated
NOTE. Adverse events (AEs) that were recorded multiple times for any patient are reported only once in the table according to the worst grade. GI and metabolic
AEs occurred most frequently, followed by constitutional symptoms, blood and bone marrow, and pain. AEs are included in the table for all categories of
“relatedness,” including “Not related.”
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; GU, genitourinary.
Table A3. Comparison of Metabolic and Anatomic Best Overall Response, Response Rate, and Disease Control Rates
Observed Best Overall Response
Metabolic Classification
PD PR SD Total
Frequency % Frequency % Frequency % Frequency %
Metabolic response classification
PD 4 23.5 0 0.0 0 0.0 4 23.5
PR 1 5.9 4 23.5 0 0.0 5 29.4
SD 4 23.5 1 5.9 3 17.7 8 47.1
Total 9 52.9 5 29.4 3 17.7 17 100.0
Observed Response Rate
No Yes Total
Frequency % Frequency % Frequency %
Metabolic response rate
No 11 64.7 1 5.9 12 70.6
Yes 1 5.9 4 23.5 5 29.4
Total 12 70.6 5 29.4 17 100.0
Observed Disease Control Rate
No Yes Total
Frequency % Frequency % Frequency %
Metabolic disease-control rate†
No 4 23.5 0 0.0 4 23.5
Yes 5 29.4 8 47.1 13 76.5
Total 9 52.9 8 47.1 17 100.0
NOTE. Frequency missing for all  5.
Abbreviations: PD, progressive disease; PR, partial response; SD, stable disease.
McNemar’s test P  .99.
†McNemar’s test P  .03.
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Fig A1. Examples of fluorescent in situ hybridization analyses. Probes were labeled by random octamer priming and hybridized after microwaving and pepsin digestion.
Adjacent sections were stained by hematoxylin and eosin to identify tumor-containing regions. The KIT locus on the chromosome 4 (Chr4) long arm was evaluated by
using a mini-contig of bacterial artificial chromosome (BAC) probes (digoxigenin-labeled BACs C00-840L10 and RP11-586A2) cohybridized with a biotinylated
chromosome 2 (Chr2) centromeric probe, the latter serving as a copy number control, given that the chromosome 2 centromeric region is rarely deleted or gained in
melanoma. Signal detection was strepavidin-Alexa598 (red) for the chromosome 2 centromere, and fluorescein isothiocyanate-antidigoxigenin (green) for KIT. Two
hundred nuclei were analyzed by using guidelines proposed by Hopman et al (Curr Protoc Cytom Chapter 8:Unit 8.5, 2001). (A,B: patient 102) Both chromosome 4 and
KIT were increased (low-level gain of a major part of chromosome 4). Chromosome 2 centromere was not increased (better copy number was a neutral indicator of
genome ploidy). A: Chr2, red; KIT, green; B: Chr4, red; KIT, green. (C,D; patient 116) High-level/localized KIT amplification, not extending to chromosome 4 centromere.
Both chromosome 2 and chromosome 4 centromeres were informative for copy number reference. C: Chr2, red; KIT, green; D: Chr4, red; KIT, green. (E) Examples
of KIT/chromosome 2 and KIT/chromosome 4 ratios.
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